arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Lantheus Holdings, Inc.

LNTH
$100.70 ▼ -0.45 (-0.44%) at close
Healthcare ·In Vitro & In Vivo Diagnostic Substances ·USIn Vitro & In Vivo Diagnostic Substances
14 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
85
Health
Excellent
Bullish
auto_awesome

Analytical Summary

Lantheus Holdings, Inc. shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $6.8B
Dividend Yield —
Revenue Growth 0.5% ↘
Op. Margin 20.2% ↘
ROIC 21.2% ↘
FCF / Share $5.78 ↘
Trailing P/E 29.1x
Price / Book 6.0x
FCF Yield 5.7%
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

14-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.54B
↑ +0.5% —
Net Income Profit after all expenses
$233.56M
↓ -25.2% —
Operating Margin Operating profit as % of sales
20.2%
↓ -32.3% 75th
FCF / Share Free cash flow per share
$5.78
↓ -26.6% —
Long-Term Debt Long-term obligations
$174.76M
↓ -20.0% —
trending_up

Bullish Indicators

  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability ↑
80
Returns
88
Financial Health
89
Cash Quality
83

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 14 years · 52 quarters